KRAS and Miyoshi myopathy: The identification of these alterations also led to the development of targeted therapies to treat MM patients carrying specific driver mutations, such as Selumetinib (KRAS), Cobimetinib (NRAS), Palbociclib [del(1p), t(11;14) or t(6;14)], and Vemurafenib (BRAF) [90,91,92,93,94].